9th International Congress on Autoimmunity

On March 26. – 30. 2014 over 2000 scientists from around the world met in Nice for the 9th International Congress on Autoimmunity. Immunologists from basic research, industry and over 700 clinicians presented and discussed the latest developments in the research and treatment of auto-immune diseases. MetrioPharm’s president of the board and CSO, Dr. Wolfgang Brysch presented new results on the efficacy and safety of MP1000 in disease models of rheumatoid arthritis. In the context of all currently available arthritis treatments as well as the other new therapies in development, which were discussed at this conference, it became clear that MP1000 is very unique in the field of immune regulating drugs. All other drugs that were presented at the conference act more or less as immune-suppressors and thus inevitably lead to an increased risk of severe infections. MP1000 is the first and currently only drug which overcomes this inherent risk of all classical immune-suppressive drugs by having both anti-inflammatory and anti-infective effects at the same time. The results presented by MetrioPharm which clearly demonstrate this twofold effect created a highly positive response from the scientific audience and keen interest in this new drug principle.

Obesity – An Epidemic Inflammatory Disease

According to the World Health Organization (WHO) “obesity has reached epidemic proportions”. Since 1980, the number of obese persons almost doubled and about 2.8 million people die each year as a result of being overweight or obese. A recent research article in the prestigious FASEB Journal[1] describes an important link between obesity and inflammation. „This important new finding links obesity and high fat high sugar diets with changes in immune cells and inflammatory status, highlighting an emerging realization that obesity is an inflammatory disease,“ said David P. Fairlie, Ph.D., study author from the Institute for Molecular
Bioscience at the University of Queensland, in Bribane, Australia. “Drugs designed to block certain inflammatory proteins, as in this report, may be able to prevent and treat obesity, which in turn is a major risk factor for type 2 diabetes, heart disease, stroke, kidney failure, limb amputation, and cancers.”

“These findings underscore the great importance of new and safer anti-inflammatory drugs” comments Wolfgang Brysch MD, president of MetrioPharm. “If we need to treat widespread, chronic diseases like obesity with anti-inflammatory drugs, the superior safety profile of MP1000 becomes an even greater advantage over present therapeutic options.”

Copyright © 2014 MetrioPharm AG, All rights reserved.